GoKawiilResearchers question Prozac evidence for child depression, cite 2006 Iran trial
A team led by psychiatrist Richard Lyus and researcher Florian Naudet published an analysis in Cochrane Evidence Synthesis and Methods arguing that a 2006 Iranian trial of 40 children had data flaws serious enough to undermine its reliability. They say this single study has disproportionately influenced clinical guidelines recommending fluoxetine (Prozac) for depression in children and adolescents, though they are not calling for doctors to stop prescribing it.
GoKawiil's interpretation of the reporting above, not reported fact.
The case illustrates how one problematic 'zombie trial' can distort systematic reviews that shape treatment guidelines for widely prescribed drugs, according to Naudet, who says such clear-cut examples are rare despite repeated warnings about flawed studies skewing medical evidence. The authors suggest guideline committees should reassess whether Prozac's recommendation for pediatric depression remains justified once this trial's data are properly weighed, though the ultimate clinical decision rests with those committees.
- A 2006 Iranian trial of 40 children may have skewed evidence supporting Prozac for pediatric depression
- Researchers call for guideline committees to review recommendations, not for immediate prescribing changes
- The case highlights broader risks of flawed trials corrupting systematic medical evidence reviews
Source: nature.com — Van Noorden, 2026-10-02
Published there as: “Prozac use for childhood depression skewed by single flawed medical trial”
Read the original report → The summary and analysis above are GoKawiil's own, written from reporting by the source above. Facts and quotes belong to the original publisher.